MCID: ALK015
MIFTS: 37

Alk-Positive Anaplastic Large Cell Lymphoma malady

Categories: Cancer diseases, Blood diseases, Rare diseases, Immune diseases

Aliases & Classifications for Alk-Positive Anaplastic Large Cell Lymphoma

Aliases & Descriptions for Alk-Positive Anaplastic Large Cell Lymphoma:

Name: Alk-Positive Anaplastic Large Cell Lymphoma 56
Anaplastic Large Cell Lymphoma, Alk-Positive 69
Anaplastic Large Cell Lymphoma, Alk Negative 69
Alk+ Anaplastic Large Cell Lymphoma 56
Alk+ Alcl 56

Characteristics:

Orphanet epidemiological data:

56
alk-positive anaplastic large cell lymphoma
Inheritance: Not applicable; Age of onset: Adolescent,Adult,Childhood;

Classifications:



External Ids:

Orphanet 56 ORPHA300895
ICD10 via Orphanet 34 C84.6
ICD10 33 C84.6 C84.7

Summaries for Alk-Positive Anaplastic Large Cell Lymphoma

MalaCards based summary : Alk-Positive Anaplastic Large Cell Lymphoma, also known as anaplastic large cell lymphoma, alk-positive, is related to alk-negative anaplastic large cell lymphoma and anaplastic large cell lymphoma. An important gene associated with Alk-Positive Anaplastic Large Cell Lymphoma is ALK (ALK Receptor Tyrosine Kinase), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Glioma. The drugs Crizotinib and Protein Kinase Inhibitors have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and breast.

Related Diseases for Alk-Positive Anaplastic Large Cell Lymphoma

Graphical network of the top 20 diseases related to Alk-Positive Anaplastic Large Cell Lymphoma:



Diseases related to Alk-Positive Anaplastic Large Cell Lymphoma

Symptoms & Phenotypes for Alk-Positive Anaplastic Large Cell Lymphoma

Drugs & Therapeutics for Alk-Positive Anaplastic Large Cell Lymphoma

Drugs for Alk-Positive Anaplastic Large Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 77)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Crizotinib Approved Phase 3,Phase 2,Phase 1 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
2 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1
3
Doxorubicin Approved, Investigational Phase 2,Phase 1 23214-92-8 31703
4
Daunorubicin Approved Phase 2 20830-81-3 30323
5
Vincristine Approved, Investigational Phase 1, Phase 2 2068-78-2, 57-22-7 5978
6
Etoposide Approved Phase 2,Phase 1 33419-42-0 36462
7
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 50-18-0, 6055-19-2 2907
8
Lenalidomide Approved Phase 1, Phase 2 191732-72-6 216326
9
Cortisone acetate Approved Phase 2 1950-04-4, 50-04-4 5745
10
Prednisone Approved, Vet_approved Phase 2,Phase 1 53-03-2 5865
11
alemtuzumab Approved, Investigational Phase 2 216503-57-0
12
Ceritinib Approved Phase 1, Phase 2 1032900-25-6
13
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
14
Cytarabine Approved, Investigational Phase 2 147-94-4 6253
15
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
16
Ifosfamide Approved Phase 2 3778-73-2 3690
17
Mechlorethamine Approved Phase 2 51-75-2 4033
18
leucovorin Approved, Nutraceutical Phase 2 58-05-9 54575, 6560146 143
19
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
20
Doxil Approved June 1999 Phase 2,Phase 1 31703
21 Podophyllotoxin Phase 2 518-28-5
22
Cortisone Phase 2 53-06-5 222786
23 Alkylating Agents Phase 2,Phase 1
24 glucocorticoids Phase 2,Phase 1
25 Topoisomerase Inhibitors Phase 2,Phase 1
26 Nucleic Acid Synthesis Inhibitors Phase 2,Phase 1
27 Dermatologic Agents Phase 2
28 Hormone Antagonists Phase 2,Phase 1
29 Hormones Phase 2,Phase 1
30 Angiogenesis Inhibitors Phase 1, Phase 2
31 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2,Phase 1
32 Angiogenesis Modulating Agents Phase 1, Phase 2
33 Anti-Bacterial Agents Phase 2,Phase 1
34 Immunoconjugates Phase 2,Phase 1
35 Etoposide phosphate Phase 2,Phase 1
36 Immunoglobulins Phase 2,Phase 1
37 Anti-Infective Agents Phase 1, Phase 2
38 Antibodies, Monoclonal Phase 2,Phase 1
39 Immunosuppressive Agents Phase 2,Phase 1
40 Anti-Inflammatory Agents Phase 2,Phase 1
41 Keratolytic Agents Phase 2
42 Antibiotics, Antitubercular Phase 2,Phase 1
43 Antibodies Phase 2,Phase 1
44 Antimitotic Agents Phase 2,Phase 1
45 Antirheumatic Agents Phase 2,Phase 1
46 Antineoplastic Agents, Alkylating Phase 2,Phase 1
47 Antineoplastic Agents, Hormonal Phase 2,Phase 1
48 Antineoplastic Agents, Phytogenic Phase 2,Phase 1
49 Dexamethasone acetate Phase 2 1177-87-3
50
protease inhibitors Phase 2

Interventional clinical trials:

(show all 11)
id Name Status NCT ID Phase
1 ALTA-1L Study: A Phase 3 Study of Brigatinib Versus Crizotinib in ALK-positive Advanced Non-Small Cell Lung Cancer Patients Recruiting NCT02737501 Phase 3
2 Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas Recruiting NCT02419287 Phase 2
3 AT13387 in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Diffuse Large B-cell Lymphoma Recruiting NCT02572453 Phase 2
4 Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma Recruiting NCT03113500 Phase 2
5 Combination Chemotherapy and Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma Recruiting NCT02561273 Phase 1, Phase 2
6 Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas Active, not recruiting NCT00069238 Phase 2
7 A Phase 2, Multicenter, Randomized Study of AP26113 Active, not recruiting NCT02094573 Phase 2
8 Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma Not yet recruiting NCT02729961 Phase 1, Phase 2
9 Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma Suspended NCT01979536 Phase 2
10 A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer Recruiting NCT00585195 Phase 1
11 An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer No longer available NCT02784158

Search NIH Clinical Center for Alk-Positive Anaplastic Large Cell Lymphoma

Genetic Tests for Alk-Positive Anaplastic Large Cell Lymphoma

Anatomical Context for Alk-Positive Anaplastic Large Cell Lymphoma

MalaCards organs/tissues related to Alk-Positive Anaplastic Large Cell Lymphoma:

39
Bone, Bone Marrow, Breast, Testes, Myeloid, B Cells, Skin

Publications for Alk-Positive Anaplastic Large Cell Lymphoma

Articles related to Alk-Positive Anaplastic Large Cell Lymphoma:

(show top 50) (show all 98)
id Title Authors Year
1
Arsenic trioxide degrades NPM-ALK fusion protein and inhibits growth of ALK-positive anaplastic large cell lymphoma. ( 27795556 )
2016
2
ALK-positive anaplastic large-cell lymphoma with marked leukemoid reaction and hemophagocytic lymphohistiocytosis. ( 27563714 )
2016
3
Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes. ( 27793034 )
2016
4
Fine-needle aspiration cytology yield as a basis for morphological, molecular, and cytogenetic diagnosis in alk-positive anaplastic large cell lymphoma with atypical clinical presentation. ( 27468968 )
2016
5
A positive feedback loop involving the Wnt/I^-catenin/MYC/Sox2 axis defines a highly tumorigenic cell subpopulation in ALK-positive anaplastic large cell lymphoma. ( 27821172 )
2016
6
Successful allogeneic bone marrow transplantation with reduced intensity conditioning regimen for a pediatric relapsed ALK positive anaplastic large cell lymphoma. ( 27498729 )
2016
7
Remission of an extensively pre-treated relapsing/refractory ALK-positive anaplastic large cell lymphoma following metronomic therapy. ( 26734914 )
2016
8
ALK-positive anaplastic large cell lymphoma with prominent bone involvement in a 13-year-old boy. ( 26834485 )
2016
9
ALK positive Anaplastic Large Cell Lymphoma of the Thoracic Spine. ( 27761194 )
2016
10
ALK-positive anaplastic large cell lymphoma with soft tissue involvement in a young woman. ( 27445489 )
2016
11
Primary central nervous system ALK-positive anaplastic large cell lymphoma in an adult: A rare case report. ( 27930548 )
2016
12
Intra-abdominal ALK-positive anaplastic large cell lymphoma in a patient with neurofibromatosis type 1. ( 26272700 )
2015
13
The NADPH oxidase NOX5 protects against apoptosis in ALK-positive anaplastic large-cell lymphoma cell lines. ( 25797883 )
2015
14
Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma. ( 25421750 )
2015
15
Metachronous classical Hodgkin's lymphoma and ALK-positive anaplastic large cell lymphoma. ( 25938345 )
2015
16
ALK-positive anaplastic large cell lymphoma: an evolving story. ( 25961700 )
2015
17
Endobronchial ALK-Positive Anaplastic Large Cell Lymphoma Presenting Massive Hemoptysis. ( 26508931 )
2015
18
ALK-positive anaplastic large cell lymphoma with prominent bone involvement. ( 26018037 )
2015
19
ALK Positive Anaplastic Large Cell Lymphoma Presenting as Extensive Bone Involvement. ( 25738071 )
2015
20
ALK-positive anaplastic large cell lymphoma presenting with hemophagocytic lymphohistiocytosis. ( 26114236 )
2015
21
MicroRNA and ALK-positive anaplastic large cell lymphoma. ( 25961697 )
2015
22
STAT1 is phosphorylated and downregulated by the oncogenic tyrosine kinase NPM-ALK in ALK-positive anaplastic large-cell lymphoma. ( 25921060 )
2015
23
Targeting autophagy enhances the anti-tumoral action of crizotinib in ALK-positive anaplastic large cell lymphoma. ( 26338968 )
2015
24
Silibinin suppresses NPM-ALK, potently induces apoptosis and enhances chemosensitivity in ALK-positive anaplastic large cell lymphoma. ( 26133723 )
2015
25
Correction: Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma. ( 26420623 )
2015
26
ALK-positive anaplastic large cell lymphoma with an unusual alveolar growth pattern. ( 25674293 )
2014
27
STAT3-mediated activation of microRNA cluster 17~92 promotes proliferation and survival of ALK-positive anaplastic large cell lymphoma. ( 23975180 )
2014
28
Diagnosis of ALK-positive anaplastic large cell lymphoma based on CD30 testing. ( 25855891 )
2014
29
Editor in Chief: Response to Eyre etA al. "ALK-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease" ( 24953081 )
2014
30
Brain metastasis of ALK positive anaplastic large cell lymphoma after a long-term disease free survival in an old adult. ( 24696735 )
2014
31
Diagnosis of ALK-positive anaplastic large cell lymphoma based on CD30 testing. ( 24852617 )
2014
32
ALK Positive Anaplastic Large Cell Lymphoma With Pure Leptomeningeal Involvement: Unique Case Report and Review of the Literature. ( 24407988 )
2014
33
Early assessment of minimal residual disease identifies patients at very high relapse risk in NPM-ALK-positive anaplastic large-cell lymphoma. ( 24297868 )
2014
34
Anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma (ALCL) of breast in a patient without a breast implant. ( 25971833 )
2014
35
Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma. ( 24509625 )
2014
36
Identification of a novel crosstalk between casein kinase 2I+ and NPM-ALK in ALK-positive anaplastic large cell lymphoma. ( 23153582 )
2013
37
Primary central nervous system ALK positive anaplastic large cell lymphoma with predominantly leptomeningeal involvement in an adult. ( 23549832 )
2013
38
Simultaneous cytomorphological and multiparameter flow cytometric analysis of ALK-positive anaplastic large cell lymphoma in children. ( 23420373 )
2013
39
Leukemic phase of ALK-positive anaplastic large cell lymphoma. ( 23610781 )
2013
40
Intravascular large B-cell lymphoma occurring 25 years after treatment of ALK-positive anaplastic large cell lymphoma. ( 23488602 )
2013
41
Use of targeted therapy for refractory ALK-positive anaplastic large cell lymphoma as a bridging strategy prior to allogeneic transplantation. ( 22820970 )
2013
42
Disheveled proteins promote cell growth and tumorigenicity in ALK-positive anaplastic large cell lymphoma. ( 23022960 )
2013
43
ALK-positive anaplastic large cell lymphoma limited to the skin: clinical, histopathological and molecular analysis of 6 pediatric cases. A report from the ALCL99 study. ( 22773605 )
2013
44
ALK-positive anaplastic large cell lymphoma presenting as intradural spinal mass: first reported case and review of literature. ( 23082771 )
2013
45
The heat shock protein-90 co-chaperone, Cyclophilin 40, promotes ALK- positive, anaplastic large cell lymphoma viability and its expression is regulated by the NPM-ALK oncoprotein. ( 22681779 )
2012
46
The expression and oncogenic effects of the embryonic stem cell marker SALL4 in ALK-positive anaplastic large cell lymphoma. ( 22743134 )
2012
47
ALK-positive anaplastic large cell lymphoma with TPM3-ALK translocation. ( 22591683 )
2012
48
Unusual central nervous system presentation of ALK-positive anaplastic large cell lymphoma in a child. ( 23135034 )
2012
49
Aberrant expression and biological significance of Sox2, an embryonic stem cell transcriptional factor, in ALK-positive anaplastic large cell lymphoma. ( 22885405 )
2012
50
Aberrant expression of the transcriptional factor Twist1 promotes invasiveness in ALK-positive anaplastic large cell lymphoma. ( 22155737 )
2012

Variations for Alk-Positive Anaplastic Large Cell Lymphoma

Expression for Alk-Positive Anaplastic Large Cell Lymphoma

Search GEO for disease gene expression data for Alk-Positive Anaplastic Large Cell Lymphoma.

Pathways for Alk-Positive Anaplastic Large Cell Lymphoma

Pathways related to Alk-Positive Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 12)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.92 JAK3 MCL1 MUC1 STAT3
2
Show member pathways
12.42 ALK DVL2 JAK3 STAT3
3
Show member pathways
12.15 JAK3 MCL1 STAT3
4
Show member pathways
11.57 JAK3 MCL1 STAT3
5
Show member pathways
11.43 MCL1 STAT3
6 11.3 JAK3 STAT3
7 11.27 MCL1 NPM1
8 11.27 DVL2 JAK3 STAT3
9
Show member pathways
11.05 JAK3 STAT3
10
Show member pathways
10.99 JAK3 STAT3
11 10.98 JAK3 MCL1 MUC1 STAT3
12 10.93 JAK3 STAT3

GO Terms for Alk-Positive Anaplastic Large Cell Lymphoma

Biological processes related to Alk-Positive Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein oligomerization GO:0051259 9.32 DVL2 NPM1
2 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.26 MUC1 NPM1
3 response to cytokine GO:0034097 9.16 MCL1 STAT3
4 regulation of apoptotic process GO:0042981 9.13 ALK JAK3 MCL1
5 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 8.62 JAK3 STAT3

Molecular functions related to Alk-Positive Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein phosphatase binding GO:0019903 8.96 JAK3 STAT3
2 protein kinase binding GO:0019901 8.8 DVL2 NPM1 STAT3

Sources for Alk-Positive Anaplastic Large Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....